54 Bioanalytical Services CRO & CDMO vendors

What is bioanalytical services and when do you need it?

Bioanalytical work is the measurement layer of drug development. It answers a deceptively simple question: how much drug, and how much of its metabolites, is actually in the blood, plasma, serum, or tissue at a given time. Without that number, your pharmacokinetics are guesses, your toxicokinetics have no exposure to anchor the NOAEL to, and your dose selection rests on nothing. A bioanalytical lab builds the assay that produces that number, proves the assay is reliable, then runs your study samples through it.

You first need it in preclinical, the moment in vivo PK and early toxicology generate samples that have to be quantified. It does not stop there. The same discipline carries through GLP IND-enabling toxicokinetics, then into every clinical phase, where plasma and urine samples from Phase 1 through Phase 3 are analyzed to support PK, dose-proportionality, drug-drug interaction, and bioequivalence claims. This is why the service sits at the preclinical stage on the BioBridgeX grid but is sourced as both CRO and CDMO work: the assay groups that support nonclinical studies often support clinical samples too, and some sit inside a CDMO's QC and release operation.

The work splits cleanly by molecule type, and that split decides which vendor you want. Small molecules and many peptides are quantified by LC-MS/MS (liquid chromatography tandem mass spectrometry), the workhorse platform for sensitivity and specificity. Large molecules (antibodies, recombinant proteins, and other biologics) are usually measured by ligand-binding assays such as ELISA or the Meso Scale Discovery (MSD) electrochemiluminescence platform, though LC-MS is increasingly used for peptides and proteins too. Biologics also drag in immunogenicity testing: anti-drug antibody (ADA) and neutralizing-antibody (NAb) assays, where the patient's immune response to the drug is itself the readout. A lab that is excellent at small-molecule LC-MS/MS may be the wrong choice for an ADA assay on a complex biologic, and vice versa.

What does a bioanalytical services CRO actually do?

The work runs in two phases that buyers should price and schedule separately. First comes method development and validation: building an assay that detects your specific compound in the right matrix at the lower limit of quantification (LLOQ) your program needs, then proving it performs. For regulated studies that validation follows the FDA and ICH M10 bioanalytical method validation guidance and covers accuracy, precision, selectivity, calibration range, matrix effect, recovery, carryover, dilution linearity, and analyte stability (bench-top, freeze-thaw, long-term frozen). Method development is frequently the hidden critical path of a whole program, because your PK and tox samples cannot be read until the validated method exists, and samples sit in a freezer accruing stability questions while they wait.

Second comes sample analysis: running the actual study samples (incurred samples, calibration standards, and quality-control samples) through the validated method, then reporting the concentration data with the audit trail a regulator expects. Regulated runs include incurred sample reanalysis (ISR), a reproducibility check that reanalyzes a subset of study samples to confirm the original results hold up. For biologics programs the same group typically runs the ADA and NAb tiered testing (screen, confirm, titer) that supports the immunogenicity sections of your submission.

Around those two phases sit the things that make data usable: chain-of-custody and sample receipt and storage at controlled temperatures, biomarker assays that overlap with the bioanalytical group (flow cytometry, qPCR, multiplex panels for pharmacodynamic readouts), and the regulatory-grade documentation (validation reports, analytical run records, and the bioanalytical report itself) that gets compiled into your IND, NDA, or BLA. Good labs also flag problems early, a failing stability result or an unexpected metabolite, rather than handing you a clean-looking report that does not survive an FDA inspection.

How do you choose a bioanalytical services CRO or CDMO?

Match the platform to your molecule before you look at a single quote, then weigh the practical things that decide whether a program runs on time. The cheapest method that cannot hit your LLOQ, or a validated method you cannot defend in an inspection, is the most expensive outcome there is. Run two or three vendors against the same written scope (the analyte, the matrix, the species or population, the sensitivity, and the regulatory standard) so the quotes are actually comparable rather than measuring different work.

• Quality and GxP status: confirm whether you need GLP (21 CFR Part 58, for IND-enabling toxicokinetics), GCLP or GCP-aligned conduct for clinical sample analysis, or fit-for-purpose non-GLP for exploratory work. Ask for the recent FDA inspection history and whether method validation will follow FDA and ICH M10. Paying GLP premiums for an exploratory screen, or running a pivotal study fit-for-purpose, both cost you later.
• Platform and modality fit: LC-MS/MS depth for small molecules and peptides, ligand-binding (ELISA, MSD) and immunogenicity (ADA, NAb tiered testing) for biologics, and the right approach for oligonucleotides, ADCs (which need both the conjugate and free-payload measured), or cell and gene therapy analytes such as qPCR-based vector quantification.
• Sensitivity and method capability: ask whether they can already detect your compound at the LLOQ a low-dose program needs in the matrices you care about, not just whether they own the instrument. A method that already runs for your analyte class beats a vague capability claim.
• Capacity and lead time: method development and validation is often the rate-limiting step, so ask about current queue, instrument availability, and realistic timelines to a validated method and to first sample results. A great lab booked solid for months can be slower than a good lab with an open slot.
• Region and regulatory track record: confirm experience with the agency you plan to file with (FDA, EMA, PMDA, NMPA) and a clean record supporting submissions, since bioanalytical data underpins your entire PK and safety story.
• Data quality, IP, and confidentiality: insist on full audit trails, validated software (21 CFR Part 11), ISR for regulated runs, transparent reporting of failed runs and stability issues, and clear terms on who owns the method and how data and samples transfer back to you under a CDA.